Table 3.
Histopathological factors (and summary values) assessed as covariates of liver R2* value
| Covariate | 1.5T (n=89) | 3T (n=119) | p-values (1.5T vs 3T) | FLINT (Adults, n=101) | CyNCh (Children, n=107) | p-values (FLINT vs CyNCH) |
|---|---|---|---|---|---|---|
| Steatosis grade* | 0.53 | <0.001 | ||||
| Grade 0 | 1% (1/89) | 0% (0/119) | 1% (1/101) | 0% (0/107) | ||
| Grade 1 | 27% (24/89) | 23% (27/119) | 33% (33/101) | 17% (18/107) | ||
| Grade 2 | 30% (27/89) | 37% (44/119) | 40% (40/101) | 29% (31/107) | ||
| Grade 3 | 42% (37/89) | 40% (48/119) | 27% (27/101) | 54% (58/107) | ||
| Steatosis location | 0.20 | <0.001 | ||||
| Zone 3 (acinar) | 39% (35/89) | 43% (51/119) | 43% (43/101) | 40% (43/107) | ||
| Zone 1 (periportal) | 13% (12/89) | 5% (6/119) | 0% (0/101) | 17% (18/107) | ||
| Azonal | 18% (16/89) | 19% (23/119) | 32% (32/101) | 7% (7/107) | ||
| Panacinar | 29% (26/89) | 33% (39/119) | 26% (26/101) | 36% (39/107) | ||
| Hepatocyte ballooning score | 0.74 | <0.001 | ||||
| Score 0 | 33% (29/89) | 38% (45/119) | 15% (15/101) | 55% (59/107) | ||
| Score 1 | 34% (30/89) | 31% (37/89) | 35% (35/101) | 30% (32/107) | ||
| Score 2 | 34% (30/89) | 31% (37/89) | 50% (51/101) | 15% (16/107) | ||
| Lobular inflammation score | 0.070 | 0.35 | ||||
| Score 1 | 43% (38/89) | 31% (37/119) | 33% (33/101) | 39% (42/107) | ||
| Score 2 | 39% (35/89) | 55% (66/119) | 49% (49/101) | 49% (52/107) | ||
| Score 3 | 18% (16/89) | 13% (16/119) | 19% (19/101) | 12% (13/107) | ||
| Portal inflammation score | 0.51 | 0.66 | ||||
| Score 0 | 4% (4/89) | 8% (10/119) | 7% (7/101) | 7% (7/107) | ||
| Score 1 | 73% (65/89) | 68% (81/119) | 67% (68/101) | 73% (78/107) | ||
| Score 2 | 22% (20/89) | 24% (28/119) | 26% (26/101) | 21% (22/107) | ||
| NAFLD activity score | 4.9 ± 1.4 | 4.9 ± 1.4 | 0.75 | 5.1 ± 1.4 | 4.7 ± 1.4 | <0.05 |
| Fibrosis stage* | 0.99 | <0.001 | ||||
| Stage 0 | 20% (18/89) | 22% (26/119) | 16% (16/101) | 26% (28/107) | ||
| Stage 1 | 34% (30/89) | 34% (40/119) | 24% (24/101) | 43% (46/107) | ||
| Stage 2 | 19% (17/89) | 19% (23/119) | 26% (26/101) | 13% (14/107) | ||
| Stage 3 | 26% (23/89) | 24% (28/119) | 33% (33/101) | 17% (18/107) | ||
| Stage 4 | 1% (1/89) | 2% (2/119) | 2% (2/101) | 1% (1/107) | ||
| Lipid droplet size* | 0.99 | <0.01 | ||||
| Predominantly large droplet | 70% (62/89) | 69% (82/119) | 78% (79/101) | 61% (65/107) | ||
| Mixed large and small droplet | 28% (25/89) | 26% (31/119) | 17% (17/101) | 36% (39/107) | ||
| Predominantly small droplet | 2% (2/89) | 5% (6/119) | 5% (5/101) | 3% (3/107) | ||
| Glycogenosis | 0.54 | 0.92 | ||||
| Not present | 55% (49/89) | 49% (58/119) | 52% (53/101) | 50% (54/107) | ||
| Focal, involving <50% of hepatocytes | 24% (21/89) | 24% (28/119) | 24% (24/101) | 23% (25/107) | ||
| Diffuse, involving >= 50% of hepatocytes | 21% (19/89) | 28% (33/119) | 24% (24/101) | 26% (28/107) | ||
| Hepatocellular iron grade* | 0.45 | <0.001 | ||||
| Grade 0 | 85% (75/88) | 80% (93/116) | 70% (68/97) | 93% (100/107) | ||
| Grade 1 | 12% (10/88) | 17% (20/116) | 24% (23/97) | 7% (7/107) | ||
| Grade 2 | 3% (3/88) | 3% (3/116) | 6% (6/97) | 0% (0/107) | ||
| Non-hepatocellular iron grade* | 0.41 | <0.001 | ||||
| Grade 0 | 86% (76/88) | 81% (94/116) | 69% (67/97) | 96% (103/107) | ||
| Grade 1 | 11% (10/88) | 13% (15/116) | 22% (21/97) | 4% (4/107) | ||
| Grade 2 | 2% (2/88) | 6% (7/116) | 9% (9/97) | 0% (0/107) |
For NAFLD activity score, data are presented as mean +/− standard deviation, and p-values are for the Wilcoxon-Mann-Whitney test. For the remaining nominal and ordinal variables, data are presented as proportion (counts/total) and p-values are for the Chi-Square test.
*
For the Chi-Square test, some categories were combined due to the small number of samples in each individual category, to increase statistical robustness. These included: steatosis grade (grades 0 and 1); fibrosis stage (stages 3 and 4); lipid droplet size (mixed and predominantly small); hepatocellular iron grade (grades 1 and 2); and non-hepatocellular iron grade (grades 1 and 2).